Tradename | Company | Number | Date | Products |
---|---|---|---|---|
OMECLAMOX-PAK | Cumberland Pharmaceuticals | N-050824 DISCN | 2011-02-08 | 1 products, RLD |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
VOQUEZNA TRIPLE PAK | Phathom Pharmaceuticals | N-215152 RX | 2022-05-03 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
biaxin | New Drug Application | 2012-02-22 |
clarithromycin | ANDA | 2024-09-01 |
clarithromycin clarithromycin | ANDA | 2018-02-14 |
clarithromycin extended release | 2008-08-08 | |
lansoprazole, amoxicillin, clarithromycin | ANDA | 2024-01-23 |
omeclamox-pak | New Drug Application | 2023-08-17 |
prevpac | New Drug Application | 2010-03-15 |
voquezna dual pak voquezna triple pak | New Drug Application | 2024-08-05 |
Expiration | Code | ||
---|---|---|---|
AMOXICILLIN / CLARITHROMYCIN / VONOPRAZAN FUMARATE, VOQUEZNA TRIPLE PAK, PHATHOM | |||
2032-05-03 | GAIN | ||
2027-05-03 | NCE |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Gastritis | D005756 | EFO_0000217 | K29.7 | 2 | — | 1 | — | 1 | 4 |
Stomach ulcer | D013276 | — | K25 | — | — | 1 | — | 1 | 2 |
Duodenal ulcer | D004381 | EFO_0004607 | K26 | — | — | 1 | — | 1 | 2 |
Ulcer | D014456 | MPATH_579 | — | — | — | 2 | — | — | 2 |
Infections | D007239 | EFO_0000544 | — | — | — | 1 | — | — | 1 |
Helicobacter infections | D016481 | EFO_1000961 | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Multiple myeloma | D009101 | — | C90.0 | 1 | 1 | — | — | — | 1 |
Plasma cell neoplasms | D054219 | — | — | 1 | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
B-cell lymphoma marginal zone | D018442 | — | C88.4 | — | — | — | — | 1 | 1 |
Thrombocytopenic purpura idiopathic | D016553 | EFO_0007160 | D69.3 | — | — | — | — | 1 | 1 |
Thrombocytopenic purpura | D011696 | — | — | — | — | — | — | 1 | 1 |
Purpura | D011693 | HP_0000979 | D69.2 | — | — | — | — | 1 | 1 |
Drug common name | Clarithromycin |
INN | clarithromycin |
Description | Clarithromycin is the 6-O-methyl ether of erythromycin A, clarithromycin is a macrolide antibiotic used in the treatment of respiratory-tract, skin and soft-tissue infections. It is also used to eradicate Helicobacter pylori in the treatment of peptic ulcer disease. It prevents bacteria from growing by interfering with their protein synthesis. It has a role as an antibacterial drug, a protein synthesis inhibitor, an environmental contaminant and a xenobiotic. |
Classification | Small molecule |
Drug class | antibiotics (Streptomyces strain) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O |
PDB | — |
CAS-ID | 81103-11-9 |
RxCUI | — |
ChEMBL ID | CHEMBL1741 |
ChEBI ID | 3732 |
PubChem CID | 84029 |
DrugBank | DB01211 |
UNII ID | H1250JIK0A (ChemIDplus, GSRS) |